Loading...

Home
ETF
SCYX

SCYX

-

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

$

0.000

0.000(0.000%)

At close

0.000(0.000%)Aft-market

ET

Overview Technical News

Most Trusted AI Platform for Winning Trades

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

Home
Contact
About Us
Press

Markets

Market Analysis
Crypto
Market Movers
Stock Monitor
Economic Calendar
All US Stocks
All Cryptos

AI Strategies

AI Stock Picker
Swing Trading
SwingMax Portfolio
Quant AI Alpha Pick
CoinSwing
Daytrading Center
Crypto Radar
Patterns Detection

Resources

Blog
Tutorial
Help Center
Affiliate Program

Products

Chat With Tia
AI Screener
Backtest Playground
Featured Screeners
AI Earnings Calendar
Thematic Investing
Whales Auto Tracker

Tools

Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator

Features

Explore AI Stock Picker
Master Swing Trading
Follow SwingMax Portfolio
Discover QuantAI Alpha Pick
Follow Whales Auto Tracker
Navigate Daytrading Center
Learn Patterns Detection
Meet Financial AI Agent
Maximize AI Screener
Why Backtesting Playground
Forecast AI Earnings Prediction
Setup Stock Monitor
Deep Dive into Tech Analysis

News

Overview
Top News
Daily Market Brief
Earnings Analysis
Newswire
Stock News
Crypto News
Institution News
Congress News
Monitor News

Compare

TradingView
SeekingAlpha

SCYX News

SCYNEXIS Secures FDA QIDP Designation for SCY-247, Ensuring 10 Years of Market Exclusivity

Jan 21 2026Yahoo Finance

Scynexis Reveals Federal Support for Partnership Between Hackensack Meridian CDI and Johns Hopkins Researchers to Create Innovative Therapies, Including New Fungerps, for Resistant Fungal Infections

Nov 17 2025Newsfilter

SCYNEXIS Announces Financial Results for Q3 2025 and Shares Corporate Update

Nov 05 2025Newsfilter

Guggenheim Reiterates Buy Rating on SCYNEXIS, Adjusts Price Target to $3

Oct 28 2025Benzinga

VTYX, MEDP, INBX Surge in After-Hours Trading Following Important Announcements

Oct 23 2025NASDAQ.COM

SCYNEXIS Announces Encouraging Phase 1 Findings for Antifungal Candidate SCY-247

Sep 30 2025NASDAQ.COM

SCYNEXIS to Attend the H.C. Wainwright 27th Annual Global Conference from September 8 to 10, 2025

Aug 25 2025Newsfilter

SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 15 2025Newsfilter

SCYNEXIS to Present Preclinical Data on Second Generation IV/Oral Fungerp SCY-247 at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID)

Apr 08 2025Newsfilter

SCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate Update

Mar 12 2025Newsfilter

SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections

Dec 18 2024Newsfilter

SCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Nov 06 2024Newsfilter

SCYNEXIS To Receive $10 Mln Milestone Payment From GSK For Completed Clinical Study Report

Jul 23 2024NASDAQ.COM

SCYX Stock Earnings: SCYNEXIS Beats EPS, Misses Revenue for Q1 2024

May 09 2024Business Insider

SCYX Stock Earnings: SCYNEXIS Misses EPS, Beats Revenue for Q4 2023

Mar 29 2024Business Insider

SCYNEXIS to Participate in Guggenheim’s 6th Annual Biotechnology Conference

Jan 30 2024businesswire